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Background:  The  ﬁndings  of  our recent  study  entitled,  “Japanese  Assessment  of  Cardiac  Events  and  Sur-
vival Study  by  Quantitative  Gated  SPECT  (J-ACCESS)”  showed  that myocardial  perfusion  single  photon
emission  computed  tomography  (MPS)  can  detect  coronary  artery  disease  (CAD)  and  help  to predict  future
cardiac  events  in  patients  with  suspected  or extant  CAD.  However,  the  extent  of  the beneﬁt  conferred
by  percutaneous  coronary  intervention  (PCI)  as  an  initial  management  strategy  compared  with  optimal
medical  therapy  remains  controversial.  Little  evidence  supports  the notion  that  myocardial  ischemia
identiﬁed  using  MPS  is an  alternative  target  of  coronary  revascularization  to  reduce  the  likelihood  of
developing  cardiac  events.
Methods:  The  multicenter,  prospective  cohort  J-ACCESS  4  study  aims  to clarify  the  prognostic  impact
of  reducing  myocardial  ischemia  determined  using  electrocardiogram-gated  MPS  in  Japanese  patientscintigraphy with coronary  artery  disease.  We started  to  register  patients  in  J-ACCESS  4 at  74  facilities  during  June
2012  and  will  continue  to do  so  until  December  2013  or  until  the cohort  comprises  500 patients  who
will  participate  in the study  from  one  month  before,  until  two  months  after  stress/rest  MPS  assessment.
Imaging  data,  the  background  of  the  patients  including  coronary  risk  factors  and  treatment  before  MPS
assessments  will be  analyzed.  The  patients  will undergo  coronary  revascularization  within  two  months
after  MPS  and/or  receive  appropriate  medical  therapy.  The  second  stress/rest  MPS  will  be  performed
from  4  to  10  months  after  coronary  revascularization  or registration.  They  will be followed  up  for  over
∗ Corresponding author at: Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kawara-machi Hirokoji, Kamigyo-ku, 602-8566
yoto,  Japan. Tel.: +81 75 741 7212; fax: +81 75 741 7215.
E-mail address: nisimura@koto.kpu-m.ac.jp (T. Nishimura).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.jjcc.2013.07.006
160 M. Nanasato et al. / Journal of Cardiology 63 (2014) 159–164
one  year  after  the  second  MPS  assessment.  The  primary  endpoints  will  be  cardiac  death,  sudden  death
of  unknown  cause,  non-fatal  myocardial  infarction,  and  hospitalization  for  heart  failure.  The  secondary
endpoints will  comprise  death  due  to  all  causes  including  non-cardiac  death  and  any  cardiovascular
events.
This  study  will  be  completed  in 2015.  Here,  we  describe  the  design  of  the  J-ACCESS  4 study.
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Stable coronary artery disease (CAD) has been widely treated
sing coronary revascularization, which also reduces the inci-
ence of death and myocardial infarction (MI) in patients who
resent with acute coronary syndromes [1,2]. However, the extent
f the beneﬁt conferred by percutaneous coronary intervention
PCI) as an initial management strategy over optimal medical
herapy comprising intensive medical therapy, reduction of coro-
ary risk factors, and lifestyle modiﬁcations for patients with
table CAD remains controversial [3–5]. Clinical outcomes deter-
ined in the revascularization and aggressive drug evaluation
COURAGE) trial revealed identical prognoses between optimal
edical therapy with and without PCI [6], although successful
CI for ﬂow-limiting stenoses should reduce the rates of death
nd MI.
Ischemic burden on the myocardium using stress myocardial
erfusion single photon emission computed tomography (MPS) to
easure the extent and severity of inducible ischemia inﬂuences
he prognosis of patients with CAD [7–9]. The modality can predict
ardiac events and evaluate therapeutic effects in patients with sta-
le CAD. A higher ischemic burden on the myocardium is associated
ith a higher frequency of cardiac events such as cardiac death,
I,  and a need for coronary revascularization. Observational data
uggest that coronary revascularization provides a survival beneﬁt
ver medical therapy when ischemia during stress MPS  is moderate
o severe [8,10].
Our previous J-ACCESS (Japanese Assessment of Cardiac Events
nd Survival Study by Quantitative Gated SPECT) and other studies
ave suggested that MPS  could not only be useful for predicting
he outcomes of patients with CAD [11–14] but also for estab-
ishing a regression model for their prognosis [15]. Sakatani et al.
howed in a separate study that the regression model of car-
iac events after MPS  examinations of patients with moderate to
evere ischemia was consistent with clinical outcomes at follow-
p [16]. Although we previously demonstrated that early coronary
evascularization is effective in patients with moderate to severe
yocardial ischemia on MPS  even in a Japanese population, we did
ot evaluate the effect of a reduction of myocardial ischemia in
hat study [13]. The effect of a reduction on myocardial ischemia
etermined by MPS  can be estimated using this regression model.
hus, we planned a multicenter, prospective cohort study using
lectrocardiogram (ECG)-gated MPS  to determine the progno-
tic impact of a reduction of myocardial ischemia in Japanese
atients with CAD. Details of the proposed study are described
elow.
ethodstudy title
This multicenter, prospective cohort study is entitled J-ACCECC
 (Japanese Assessment of Cardiac Event and Survival Study by
uantitative Gated SPECT 4 in patients with coronary artery dis-
ase).anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
Objectives
We  aim to determine the ability of ECG-gated MPS  to predict
the outcome of patients with CAD. The ﬁrst objective will be to
quantify the reduction in myocardial ischemia conferred by treat-
ment in such patients using MPS  imaging. The second will be to
clarify whether serial MPS  images of patients with CAD are use-
ful for predicting cardiac events. The third will be to determine
whether prognosis is improved by reducing myocardial ischemia
on MPS  compared with that in the regression model established by
the J-ACCESS study.
Sample size
We  plan to enroll 500 patients with CAD. The CREDO-Kyoto
study reported that the annual rates of cardiac death including sud-
den death, non-fatal MI,  and revascularization in a population of
this size are 1%, 1%, and 10–25%, respectively [17]. Another study
found that that annual rates of major adverse cardiac events includ-
ing cardiac death, non-fatal MI,  and stroke are about 7% [18]. The
primary and secondary endpoints will be reached by at least 4% and
10%, respectively, of patients during a period of one year. Therefore,
500 patients must be registered and followed-up for over one year
to determine the occurrence of primary end points in ≥50 patients.
Study protocol
Fig. 1 shows a schema of the study design. The registration
period is between June 1, 2012 and December 31, 2013. The patients
will be enrolled to the study one month before until two  months
after stress/rest MPS. Imaging data, patients’ backgrounds includ-
ing coronary risk factors and treatment before MPS  assessments
will be analyzed. The patients will undergo coronary revasculari-
zation within two months after MPS  and/or receive appropriate
medical therapy and a second stress/rest MPS  from 4 to 10 months
after this procedure or registration. The presence or absence of car-
diac events in all patients will be followed-up for at least one year.
The status of patients who develop cardiac events will be analyzed
at one year after the second MPS. The study should be completed
in 2015.
Inclusion criteria
The inclusion criteria for the patients are: ≥20 years of age,
scheduled to undergo stress–rest ECG-gated MPS  due to possible
or deﬁnite CAD, and one or more cardiac symptoms comprising
chest discomfort suggestive of angina, new onset of palpitations
or shortness of breath, and changes in ECG indicative of CAD (see
Appendix 1).
Exclusion criteria
Adult patients who meet any of the following conditions will be
excluded:
1. Acute coronary syndrome within three months before enrol-
ment.
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fig. 1. Study protocol of J-ACCESS 4. Patients will receive either medication alone (A) 
Not  mandatory. SPECT, single photon emission computed tomography.
. Prior diagnosis of myocardial infarction based on the following:
A. Values for cardiac biomarkers (troponin or creatinine kinase-
MB)  > 2-fold the upper reference limit.
B. Development of pathological Q waves > 2 continuous ECG
leads.
C. Imaging evidence of a loss of viable myocardium that has
become thin and cannot contract.
. Hemodialysis or peritoneal dialysis.
. Severe valvular disorder requiring surgical treatment.
. Hypertrophic or dilated cardiomyopathy.
. Severe congestive heart failure (New York Heart Association
class III or higher).
. Severe arrhythmia causing difﬁculties with ECG-gated MPS.
. Hypersensitivity to tetrofosmin or its analog.
. Judged unsuitable for the study by a physician for any other
reason.
yocardial SPECT procedure
Patients will be assessed using stress and rest MPS  with 99mTc-
etrofosmin. Pharmacological stress will be applied at each hospital
sing its standard MPS  protocols with adenosine in principle, with
ither a stress–rest or a rest–stress sequence. However, the num-
er of detectors, matrix size, number of steps, and camera rotation
anges will not be regulated, and the acquisition conditions will
ollow the protocol at each institution. ECG-gated MPS will be
erformed at both stress and rest. Gated MPS  ﬁndings will be quan-
iﬁed using QGS software (Cedars Sinai Medical Center, Los Angeles,
A, USA) at all institutions [11–14]. The imaging conditions and
mage processing procedures will be separately surveyed.valuation of MPS  ﬁndings
The MPS  images will be divided into 17 segments, and visual per-
usion defect scores in individual segments will be calculated usingication with coronary investigation (B) between ﬁrst and second SPECT evaluations.
the system described by Berman et al. [7] as 0, normal; 1, mildly
reduced; 2, moderately reduced; 3, severely reduced; and 4, absent
uptake. The same PC-based viewer software will be used in all insti-
tutions, and the image data will be submitted to a core laboratory.
Left ventricular ejection fraction (LVEF, %), end-diastolic volume
(EDV, mL), and end-systolic volume (ESV, mL)  will be obtained from
QGS analysis. Heart rates and ECG ﬁndings will also be surveyed
during stress tests.
Image interpretation committee
An image interpretation committee of eight collaborative physi-
cians will evaluate digitally submitted MPS  images in a blinded
manner to increase scoring objectivity.
Primary endpoints
The primary endpoints will be cardiac death, sudden death of
unknown cause, non-fatal MI,  and hospitalization for heart failure
(Appendix 2).
Secondary endpoints
The secondary endpoints will comprise death due to all
causes including non-cardiac death, hospitalization due to unstable
angina, revascularization by PCI or coronary artery bypass graft-
ing (CABG) except for staged PCI, or another cardiovascular event
(Appendix 2). The PCI for residual stenosis scheduled at the time
of the ﬁrst PCI procedure will be excluded from cardiac events as
staged PCI.
StatisticsThe primary and secondary endpoints of the study will be ana-
lyzed using the log rank test and the Cox proportional hazards
model.
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rganization
The executive committee comprising a principal investigator,
ice-principal investigator, and 24 other committee members will
e responsible for the planning and execution of the study. The
teering committee will be responsible for supervision and guid-
nce. The protocol committee will design the study protocol. The
nclusion committee will judge the suitability of the patients for
nrolment in the study. The image interpretation committee will be
esponsible for cooperation among the investigators who will inter-
ret the MPS  images. The ethics committee will judge the suitability
f treatment and the statistics committee will provide analytical
dvice (Appendix 3).
The staff of the J-ACCESS ofﬁce (Osaka Japan), whose specialty
s clinical trial data management and biostatistics, will manage the
ata.
The J-ACCESS 4 study is sponsored by the Japan Cardiovascular
esearch Foundation (Osaka, Japan).
thics
Approval from the review boards of all facilities involved in this
tudy is compulsory. In accordance with the Declaration of Helsinki,
ll patients will provide written, informed consent to participate in
ll study protocols before enrolment.
iscussion
The J-ACCESS 4 study will be the ﬁrst prospective cohort study to
valuate reductions in myocardial ischemia using stress/rest ECG-
ated MPS  and the prognostic impact of the reduction in myocardial
schemia on coronary revascularization in patients with stable CAD.
ther studies have compared the effects of coronary revasculari-
ation with medical therapy on the clinical outcomes of patients
ith stable CAD. Data from some trials have indicated that mortal-
ty is reduced after CABG compared with medical therapy [19,20].
owever, these studies were conducted before the availability
f current medical approaches including aspirin, beta blockers,
ggressive lipid lowering, and inhibitors of the renin angiotensin
ystem which facilitate plaque stabilization and improve endothe-
ial function [21]. Some studies have shown only that PCI decreases
he frequency of angina and improves short-term exercise perfor-
ance [3,4]. In addition, recent prospective randomized trials such
s COURAGE and the bypass angioplasty revascularization investi-
ation 2 diabetes (BARI 2D) found similar rates of cardiac events
omprising cardiac death and MI  [22]. BARI 2D evaluated high-risk
iabetic patients, and found that classifying a subset of patients
ased only on risk factors has little impact on stratifying patients
ho might beneﬁt from coronary revascularization.
All of these studies were based on patients who were diag-
osed at the time of enrollment using coronary angiography, which
as been the gold standard for a diagnosis of CAD. Other non-
nvasive modalities have been studied to diagnose CAD by means of
oronary angiography as a referral standard [23]. However, disso-
iation between stenosis on coronary angiograms and myocardial
schemia has been argued. Fractional ﬂow reserve with a pres-
ure wire is a functional measurement of stenoses on coronary
ngiograms that has been validated by stress electrocardiography,
ltrasound, and scintigraphy [24]. Cut-off values for minimal lumen
reas on intravascular ultrasound to differentiate ischemic from
on-ischemic stenoses have been advocated, as pressure wires can
irectly measure the functional value of stenoses. In one study, half
f the patients with a minimal lumen area below the cut-off value
ould be misdiagnosed as having ischemic stenoses [25,26]. Func-
ional assessment in PCI leads to better clinical outcomes regardlessdiology 63 (2014) 159–164
of the angiographic appearance of the stenosis [27]. Treating non-
ischemic stenoses by PCI is not beneﬁcial and might be harmful.
The appropriate selection of the patients for coronary revascula-
rization is pivotal in clinical practice. Guidelines emphasize that
patients should undergo a functional assessment before coronary
revascularization, in contrast to the designs of the previous studies.
Identifying and reducing myocardial ischemia must be the thera-
peutic target to improve clinical outcomes for patients with stable
CAD rather than identifying and dilating coronary stenoses.
Stress/rest MPS  has played an important role in the non-invasive
assessment of myocardial ischemia. It has the advantage over
quantitative myocardial ischemia and serial examinations of being
non-invasive. Moroi et al. performed a sub-analysis of a Japanese
prospective multicenter registry cohort study and found that early
coronary revascularization might decrease the likelihood of cardiac
events in patients with stable CAD and moderate to severe ischemia
[13]. Shaw et al. showed that adding PCI to optimal medical therapy
resulted in a greater reduction in myocardial ischemia compared
with optimal medical therapy alone, and concluded that a 5% reduc-
tion in ischemia should be a target to improve the prognosis of
patients with CAD [10]. However, the conclusion is not robust due
to the nature of the subanalysis, which did not prospectively plan to
assess the effectiveness of the reduction in ischemia. Only patients
whose coronary lesions were suitable for PCI were included, as the
aim of the main trial was to compare optimal medical therapy with
and without PCI. Although most patients with stable CAD would
be treated with drug-eluting stents, many in the study population
were actually treated with bare metal stents.
Taken together, whether reducing myocardial ischemia
improves the prognosis of patients with stable CAD remains
unclear. The results of the J-ACCESS 4 study should thus be quite
informative.
Financial support
Japan Cardiovascular Research Foundation.
Appendix 1.
Cardiac symptoms
1. Chest discomfort suggestive of angina-paroxysmal chest pain,
chest discomfort persisting for a few minutes, or pain radiating
to the left shoulder, left arm or neck.
2. New onset of palpitations or shortness of breath.
3. Changes on ECG indicative of ischemia – development of patho-
logical Q waves, ST segment elevation or depression.
Appendix 2.
Endpoint deﬁnitions
Deﬁnitions of causes of death
1. Cardiac death – judged by physicians as being due to heart fail-
ure, acute myocardial infarction (see criteria below), or other
cardiac disorders.
1) Death due to heart failure must include chest X-ray ﬁndings
attributable to cardiac dysfunction (pulmonary edema, etc.)
and respiratory distress.
2) Death due to acute myocardial infarction must meet either of
the following criteria:
(1) Typical increases and decreases (rise and gradual fall of
troponin T or I, or more rapid rise and fall of creatinine
kinase [CK] or CK-MB) in biochemical markers of myocar-
dial necrosis with at least one of the following:
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a. Ischemic symptoms.
b. Development of pathological Q waves on ECG.
c. Changes in ECG indicative of ischemia (ST segment ele-
vation or depression).
d. Coronary artery intervention.
(2) Pathological ﬁndings of acute myocardial infarction at
autopsy.
. Sudden death of unknown cause. Death in which the cause can-
not be identiﬁed within 24 h of occurrence.
. Non-cardiac death. All types of death other than those described
in 1 and 2.
Criteria for cardiovascular events other than death.
Cardiovascular events that do not lead to death are classiﬁed as:
. Non-fatal acute myocardial infarction.
Diagnosis of acute myocardial infarction (see above criteria).
. Hospitalization for heart failure.
Hospitalization for treatment after heart failure (see above
criteria).
. Hospitalization for unstable angina.
Hospitalization required for treatment, with at least one of the
following ﬁndings:
Troponin or CK-MB not elevated, related artery conﬁrmed by
CAG:
a. Chest pain persisting for at least 20 min  at rest or during min-
imal exertion.
b. New and severe chest pain.
c. Exacerbated chest pain.
. Other cardiovascular events.
Events judged by physicians to be ischemic stroke, aortic
issection or rupture, pulmonary embolism, or organ/extremity
nfarction.
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